Fundraising Fox

Helen S. Kim

Investor

Senior Managing Director at Vida Ventures · Board director at Aktis Oncology · Board director at Neogene Therapeutics · Board director at IconOVir Bio

About

Helen S. Kim offers a deep operator's perspective—having led two C‑suite biotech M&A exits (Kosan→Bristol‑Myers Squibb, Kite→Gilead) and CEO roles across big pharma and emerging biotech—bridging founders, strategics, and investors.

Contact· self-published, not guessed

Likely email· guessed from name + firm domain, not firm-published

Invests in

BiotechHealthtech

Board director at Aktis Oncology

Intro paths

→

In turn, Helen can intro founders to Aktis Oncology's investors below.

Aktis Oncology's investors · 9

Andreessen HorowitzMenlo Park · $500K – $50M checks · since 2024EcoR1 CapitalSan Francisco · since 2024Janus Henderson InvestorsLondon · since 2024MPM BioImpactBoston · $1M – $15M checks · since 2024MRL Ventures FundCambridge · $25M checks · since 2024RA CapitalBoston · since 2024RTW Investments L.P.New York · since 2024TCG CrossoverPalo Alto · since 2024Vida VenturesLos Angeles · since 2024

Co-founders at Aktis Oncology

TFTodd Foley
Todd FoleyCo-founder and Chairman
PBPatrick Baeuerle
Patrick BaeuerleCo-founder & Advisor

Board director at Neogene Therapeutics

Intro paths

→

In turn, Helen can intro founders to Neogene Therapeutics's investors below.

Neogene Therapeutics's investors · 5

EcoR1 CapitalSan FranciscoJeito CapitalParisSynconaLondon · since 2020TPGSan FranciscoVida VenturesLos Angeles · since 2020

Co-founders at Neogene Therapeutics

CL
Carsten Linnemann, PhDExecutive Officer, Director, Promoter
AN
Antonius N.M. SchumacherDirector

Board director at IconOVir Bio

Intro paths

→

In turn, Helen can intro founders to IconOVir Bio's investors below.

IconOVir Bio's investors · 4

GV (Google Ventures)Mountain View · $250K – $50M checks · since 2020Nextech InvestZurich · $648K – $3.2M checks · since 2020Vida VenturesLos Angeles · since 2024Wellington ManagementBoston · $5M – $50M checks

Deals · 2

Aktis OncologyBoard seat

via Vida Ventures · filed Oct 2024 · $175M raise

IconOVir BioBoard seat

via Vida Ventures · filed Jun 2024 · $20.2M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Per SEC Form D filings.

Colleagues at Vida Ventures

Alessandro Giacometti
Vice President, Head of Investor Relations at Vida Ventures
Alex Loftis
Principal at Vida Ventures
Alex Mejia
Executive Services Manager at Vida Ventures
Alex Shen
Director of Operations at Vida Ventures
Andy Kadlec
Senior Associate at Vida Ventures
Anita Keenan
Executive Assistant at Vida Ventures
Arie Belldegrun
Founder and Senior Managing Director at Vida Ventures
Brian Goodman
Managing Director at Vida Ventures

Frequently asked questions

Who is Helen S. Kim?
Helen S. Kim offers a deep operator's perspective—having led two C‑suite biotech M&A exits (Kosan→Bristol‑Myers Squibb, Kite→Gilead) and CEO roles across big pharma and emerging biotech—bridging founders, strategics, and investors.
Where does Helen S. Kim work?
Helen S. Kim is Senior Managing Director at Vida Ventures and Board director at Aktis Oncology and Board director at Neogene Therapeutics and Board director at IconOVir Bio.
What does Helen S. Kim invest in?
Helen S. Kim invests in Biotech, Healthtech.
What boards does Helen S. Kim sit on?
Helen S. Kim holds tracked board seats at A2 Biotherapeutics, Aktis Oncology, IconOVir Bio, ReCode Therapeutics.